Aclidiniumbromid forbedrer lungefunktion og reducerer åndenød hos patienter med KOL

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Aclidiniumbromid forbedrer lungefunktion og reducerer åndenød hos patienter med KOL. / Ulrik, Charlotte Suppli.

In: Ugeskrift for Laeger, Vol. 176, No. 28, 31.03.2014, p. 1296-1299.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Ulrik, CS 2014, 'Aclidiniumbromid forbedrer lungefunktion og reducerer åndenød hos patienter med KOL', Ugeskrift for Laeger, vol. 176, no. 28, pp. 1296-1299.

APA

Ulrik, C. S. (2014). Aclidiniumbromid forbedrer lungefunktion og reducerer åndenød hos patienter med KOL. Ugeskrift for Laeger, 176(28), 1296-1299.

Vancouver

Ulrik CS. Aclidiniumbromid forbedrer lungefunktion og reducerer åndenød hos patienter med KOL. Ugeskrift for Laeger. 2014 Mar 31;176(28):1296-1299.

Author

Ulrik, Charlotte Suppli. / Aclidiniumbromid forbedrer lungefunktion og reducerer åndenød hos patienter med KOL. In: Ugeskrift for Laeger. 2014 ; Vol. 176, No. 28. pp. 1296-1299.

Bibtex

@article{358e314c538a4743b4fc2c48672a1a22,
title = "Aclidiniumbromid forbedrer lungefunktion og reducerer {\aa}nden{\o}d hos patienter med KOL",
abstract = "Long-acting bronchodilators are central for treatment of COPD. This short review provides an overview of studies evaluating the efficacy of aclidinium bromide, a long-acting anticholinergic bronchodilator, for the treatment of COPD. Twice-daily dosing of aclidinium leads to clinically important improvements in forced expiratory volume in 1 second, health status, use of rescue medication, day-time dyspnoea and exercise tolerance. The available studies also suggest an effect on night-time dyspnoea and exacerbation rate in patients with COPD. Aclidinium seems to have potential for a significant role in the future management of COPD.",
author = "Ulrik, {Charlotte Suppli}",
year = "2014",
month = mar,
day = "31",
language = "Dansk",
volume = "176",
pages = "1296--1299",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "28",

}

RIS

TY - JOUR

T1 - Aclidiniumbromid forbedrer lungefunktion og reducerer åndenød hos patienter med KOL

AU - Ulrik, Charlotte Suppli

PY - 2014/3/31

Y1 - 2014/3/31

N2 - Long-acting bronchodilators are central for treatment of COPD. This short review provides an overview of studies evaluating the efficacy of aclidinium bromide, a long-acting anticholinergic bronchodilator, for the treatment of COPD. Twice-daily dosing of aclidinium leads to clinically important improvements in forced expiratory volume in 1 second, health status, use of rescue medication, day-time dyspnoea and exercise tolerance. The available studies also suggest an effect on night-time dyspnoea and exacerbation rate in patients with COPD. Aclidinium seems to have potential for a significant role in the future management of COPD.

AB - Long-acting bronchodilators are central for treatment of COPD. This short review provides an overview of studies evaluating the efficacy of aclidinium bromide, a long-acting anticholinergic bronchodilator, for the treatment of COPD. Twice-daily dosing of aclidinium leads to clinically important improvements in forced expiratory volume in 1 second, health status, use of rescue medication, day-time dyspnoea and exercise tolerance. The available studies also suggest an effect on night-time dyspnoea and exacerbation rate in patients with COPD. Aclidinium seems to have potential for a significant role in the future management of COPD.

M3 - Tidsskriftartikel

C2 - 25291997

VL - 176

SP - 1296

EP - 1299

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 28

ER -

ID: 137426804